Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-141 crossover study in adults with autism spectrum disorder
ACTRN12615001059550Phase 2Recruiting
- Sponsor
- University of Sydney
- Start
- Nov 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of bremelanotide in Autism Spectrum Disorder (ASD) (2 arms), sponsored by University of Sydney. Primary endpoints: Correct recognition performance in reading emotions from faces and Amount of eye gaze to the eyes of faces. Started Nov 2015; status: recruiting.
02
Drugs
bremelanotide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12615001059550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001059550.